Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.47 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.47 |
| ▸ | HINT1 | P49773 | 3/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16787413 | 0.92 | AHCY (0.59) | AHCYHPGDIMPDH2IMPDH1HINT1 | |
| SCHEMBL16787417 | 0.89 | AHCY (0.49) | AHCYHPGDIMPDH2IMPDH1HINT1 | |
| SCHEMBL16787419 | 0.84 | AHCY (0.39) | AHCYHPGDIMPDH2IMPDH1HINT1 | |
| SCHEMBL17439986 | 0.82 | AHCY (0.64) | AHCYHPGDHINT1NT5ETGM2 | |
| SCHEMBL16113892 | 0.82 | AHCY (0.64) | AHCYHPGDHINT1NT5ETGM2 | |
| SCHEMBL16113889 | 0.82 | AHCY (0.64) | AHCYHPGDHINT1NT5ETGM2 | |
| SCHEMBL17469466 | 0.82 | AHCY (0.64) | AHCYHPGDHINT1NT5ETGM2 | |
| SCHEMBL13833306 | 0.82 | AHCY (0.64) | AHCYHPGDHINT1NT5ETGM2 | |
| SCHEMBL16787423 | 0.82 | HINT1 (0.49) | AHCYHPGDIMPDH2IMPDH1HINT1 | |
| SCHEMBL16787412 | 0.79 | ALDH1A1 (0.43) | AHCYHPGDIMPDH2IMPDH1HINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315523-B2 | Cyclic dinucleosides | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150158886-A1 | CYCLIC DINUCLEOSIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158886-A1 | CYCLIC DINUCLEOSIDES | POLN, DUT, DDX21 | AHCY 4671/4885HPGD 800/4885IMPDH2 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.